Effects of chemoimmunotherapy with and without surgery in murine MBT-2 bladder tumor

T. S. Tzai, J. S.N. Lin, Nan-Haw Chow

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Using C3H/He JCr mice bearing the syngeneic MBT-2 bladder tumor, it was found that cyclophosphamide (CYC 100 mg/kg i.p.) treatment, 1 day before and 2 weeks after surgery, followed by postoperative autologous tumor vaccine immunization can be an effective adjuvant anticancer therapy. The short-term exogeneous addition of low dose IL-2 administration to the protocol provided no further benefit. Suppression of tumor growth was observed in a classical Winn assay when splenocytes were obtained on day 23 from mice receiving this effective adjuvant therapy with surgery on day 8. Splenocytes from tumor-bearing mice (TBM) treated with CYC were augmented in terms of their proliferative response to concanavalin A during the first 2 weeks after CYC treatment. Studies using 3-day TBM established that significant suppression of tumor growth and prolonged survivals were dependent upon CYC treatment being combined with tumor vaccine and/or interleukin-2; single agent treatments were ineffective.

Original languageEnglish
Pages (from-to)6-11
Number of pages6
JournalUrologia Internationalis
Volume53
Issue number1
DOIs
Publication statusPublished - 1994 Jan 1

Fingerprint

Urinary Bladder Neoplasms
Cancer Vaccines
Interleukin-2
Neoplasms
Therapeutics
Growth
Concanavalin A
Ambulatory Surgical Procedures
Cyclophosphamide
Immunization

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

@article{dbdf846d300c423795484237609740ad,
title = "Effects of chemoimmunotherapy with and without surgery in murine MBT-2 bladder tumor",
abstract = "Using C3H/He JCr mice bearing the syngeneic MBT-2 bladder tumor, it was found that cyclophosphamide (CYC 100 mg/kg i.p.) treatment, 1 day before and 2 weeks after surgery, followed by postoperative autologous tumor vaccine immunization can be an effective adjuvant anticancer therapy. The short-term exogeneous addition of low dose IL-2 administration to the protocol provided no further benefit. Suppression of tumor growth was observed in a classical Winn assay when splenocytes were obtained on day 23 from mice receiving this effective adjuvant therapy with surgery on day 8. Splenocytes from tumor-bearing mice (TBM) treated with CYC were augmented in terms of their proliferative response to concanavalin A during the first 2 weeks after CYC treatment. Studies using 3-day TBM established that significant suppression of tumor growth and prolonged survivals were dependent upon CYC treatment being combined with tumor vaccine and/or interleukin-2; single agent treatments were ineffective.",
author = "Tzai, {T. S.} and Lin, {J. S.N.} and Nan-Haw Chow",
year = "1994",
month = "1",
day = "1",
doi = "10.1159/000282623",
language = "English",
volume = "53",
pages = "6--11",
journal = "Urologia Internationalis",
issn = "0042-1138",
publisher = "S. Karger AG",
number = "1",

}

Effects of chemoimmunotherapy with and without surgery in murine MBT-2 bladder tumor. / Tzai, T. S.; Lin, J. S.N.; Chow, Nan-Haw.

In: Urologia Internationalis, Vol. 53, No. 1, 01.01.1994, p. 6-11.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of chemoimmunotherapy with and without surgery in murine MBT-2 bladder tumor

AU - Tzai, T. S.

AU - Lin, J. S.N.

AU - Chow, Nan-Haw

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Using C3H/He JCr mice bearing the syngeneic MBT-2 bladder tumor, it was found that cyclophosphamide (CYC 100 mg/kg i.p.) treatment, 1 day before and 2 weeks after surgery, followed by postoperative autologous tumor vaccine immunization can be an effective adjuvant anticancer therapy. The short-term exogeneous addition of low dose IL-2 administration to the protocol provided no further benefit. Suppression of tumor growth was observed in a classical Winn assay when splenocytes were obtained on day 23 from mice receiving this effective adjuvant therapy with surgery on day 8. Splenocytes from tumor-bearing mice (TBM) treated with CYC were augmented in terms of their proliferative response to concanavalin A during the first 2 weeks after CYC treatment. Studies using 3-day TBM established that significant suppression of tumor growth and prolonged survivals were dependent upon CYC treatment being combined with tumor vaccine and/or interleukin-2; single agent treatments were ineffective.

AB - Using C3H/He JCr mice bearing the syngeneic MBT-2 bladder tumor, it was found that cyclophosphamide (CYC 100 mg/kg i.p.) treatment, 1 day before and 2 weeks after surgery, followed by postoperative autologous tumor vaccine immunization can be an effective adjuvant anticancer therapy. The short-term exogeneous addition of low dose IL-2 administration to the protocol provided no further benefit. Suppression of tumor growth was observed in a classical Winn assay when splenocytes were obtained on day 23 from mice receiving this effective adjuvant therapy with surgery on day 8. Splenocytes from tumor-bearing mice (TBM) treated with CYC were augmented in terms of their proliferative response to concanavalin A during the first 2 weeks after CYC treatment. Studies using 3-day TBM established that significant suppression of tumor growth and prolonged survivals were dependent upon CYC treatment being combined with tumor vaccine and/or interleukin-2; single agent treatments were ineffective.

UR - http://www.scopus.com/inward/record.url?scp=0027939712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027939712&partnerID=8YFLogxK

U2 - 10.1159/000282623

DO - 10.1159/000282623

M3 - Article

VL - 53

SP - 6

EP - 11

JO - Urologia Internationalis

JF - Urologia Internationalis

SN - 0042-1138

IS - 1

ER -